Claresa S Levetan, MD, FACE
Dr Levetan is Clinical Professor at Lankenau Institute for Medical Research in Wynnewood, Pennsylvania. She received her medical degree from Emory University School of Medicine in Atlanta, Georgia, in 1983 and postgraduate training from both Emory and Beth Israel Medical Center of Mount Sinai School of Medicine in New York City, New York. Dr Levetan's academic and clinical appointments include several directorial positions in the fields of endocrinology and diabetes.
Dr Levetan currently serves as a healthcare consultant to the White House, members of Congress, and the Congressional Diabetes Caucus. She participated in many government-supported diabetes health initiatives, including the National Institutes of Health (NIH) Diabetes Prevention Program (DPP), the Centers for Disease Control and Prevention (CDC) National Diabetes Education Program (NDEP), and the National Committee for Quality Assurance (NCQA) Diabetes Quality Improvement Project (DQIP). Dr Levetan was selected as a member of the steering committee of the NIH and CDC's National Diabetes Education Program, where she led a successful research and national initiative to standardize naming conventions for glycated hemoglobin as “A1C.” This initiative resulted in increased patient awareness and improved patient self-management. Dr Levetan is also an active member of the American Diabetes Association (ADA). She has served on the Board of Directors of the American Association of Clinical Endocrinologists (AACE) and the Board of Trustees of the American College of Endocrinology (ACE). She has been an associate editor of the journals Clinical Diabetes and Diabetes Forecast, and is actively involved in reviewing diabetes articles for the Journal of the American Medical Association (JAMA), Diabetes Care, and many others.
Dr Levetan is currently conducting research in the area of pancreatic islet regeneration. Specifically, she is investigating the role of growth-promoting peptides and newly described human peptides in islet regeneration and transformation from ductal to islet cells in patients with type 1 diabetes. She is a member of the NIH's Type Genetics Consortium and also practices endocrinology at Lankenau Hospital.
Silvio E Inzucchi, MD
Dr Inzucchi is currently Professor of Medicine and Clinical Director of the Section of Endocrinology at Yale University School of Medicine in New Haven, Connecticut. He is also Director of the Yale Diabetes Center at Yale-New Haven Hospital. Dr Inzucchi graduated from Harvard Medical School in Boston, Massachusetts, in 1985 and served as an intern and resident in internal medicine at Yale-New Haven Hospital. He completed his fellowship in Endocrinology and Metabolism at Yale University School of Medicine.
Dr Inzucchi's work is published in foremost medical journals, including the New England Journal of Medicine, Journal of the American Medical Association (JAMA), and the Annals of Internal Medicine. He also serves as an ad hoc reviewer for numerous journals, including the New England Journal of Medicine, JAMA , Lancet, American Journal of Physiology, Trends in Endocrinology, Diabetes Care, Diabetes, and Diabetic Medicine. Dr Inzucchi has delivered lectures both nationally and internationally on various topics in the fields of diabetes, lipid disorders, pituitary diseases, and disorders of calcium metabolism, and in 1998 he earned the Yale University School of Medicine Teacher of the Year Award. He is currently an active member of the Endocrine Society and American Diabetes Association (ADA).
Dr Inzucchi's research interests are focused on clinical care of patients with diabetes and insulin resistance, and the cardiovascular diseases that afflict both groups. His clinical practice serves patients with difficult-to-manage diabetes, pituitary tumors, Cushing's syndrome, endocrine disorders during pregnancy, and growth hormone deficiency syndrome. His most recent research endeavors include the inpatient management of hyperglycemia, use of insulin sensitizers for secondary stroke prevention, and the evaluation of silent heart disease in patients with diabetes.
Guillermo E Umpierrez, MD, FACP, FACE
Dr Umpierrez is an Associate Professor of Medicine at Emory University School of Medicine in Atlanta, Georgia. He is also Director of the Diabetes Clinic and the Diabetes and Endocrinology Section of Grady Health Systems in Atlanta. He received his medical degree from the University of Guayaquil, Ecuador in 1979, and completed his internal medicine residency and endocrinology fellowship at Emory University School of Medicine. Dr Umpierrez's academic and clinical appointments include several positions in the fields of endocrinology, diabetes, and metabolism.
Dr Umpierrez is the recipient of numerous teaching awards, including 4 annual Best Clinical Science Professor Awards from Emory University; 3 Golden Apple Awards for Best Clinical Teacher from the Department of Medicine at Emory University; the J. Willis Hurst Outstanding Bedside Teacher Award from the Georgia Chapter of the American College of Physicians (ACP); and the Wyman P. Sloan, Jr, Attending Physician of the Year Award from Atlanta Medical Center. He is a member of the Alpha Omega Alpha Society, a fellow of the ACP and American Association of Clinical Endocrinology (AACE) and is a board member of the Atlanta Chapter of the American Diabetes Association (ADA). He has 67 scientific publications and book chapters, and has presented 64 research abstracts at national and international scientific meetings.